We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KSB AG | TG:KSB | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.76% | 665.00 | 655.00 | 675.00 | 675.00 | 660.00 | 670.00 | 108 | 22:50:02 |
RNS Number:5265Q Xenova Group PLC 03 October 2003 Xenova Group plc Offer For KS Biomedix Holdings Plc Update Not for release, publication or distribution in or into the United States, Canada, Australia or Japan Xenova Group plc ("Xenova"), 3 October 2003 RECOMMENDED OFFER FOR KS BIOMEDIX HOLDINGS PLC ("KS BIOMEDIX") ("THE OFFER") DISPATCH OF SECTION 429 NOTICES The Offer became unconditional in all respects on 15 September 2003. As at 3pm on 2 October 2003, Xenova had received valid acceptances in respect of the Offer for KS Biomedix representing 93.36 per cent. of the issued ordinary share capital of KS Biomedix. As valid acceptances of the Offer have been received in respect of over 90 per cent. of the KS Biomedix Shares to which the Offer relates, Xenova announces that statutory notices were dispatched today pursuant to section 429 of the Companies Act 1985 to KS Biomedix Shareholders who have not accepted the Offer to acquire compulsorily all the KS Biomedix Shares in respect of which valid acceptances of the Offer have not been received. The compulsory acquisition procedure is expected to be concluded on or shortly after 14 November 2003. The Offer remains open for acceptance until 14 November 2003. KS Biomedix Shareholders who have not yet accepted the Offer are reminded to complete and return their Form of Acceptance in accordance with the instructions contained therein as soon as possible. Terms defined in the Offer Document dated 14 August 2003 have the same meaning in this announcement. Enquiries: David Oxlade, Xenova 01753 706 600 David Rasouly, Nomura 020 7521 2000 David Yates, Financial Dynamics 020 7831 3113 Nomura is acting exclusively for Xenova in connection with the Offer and is not advising any other person or treating any other person as its client in relation thereto and will not be responsible to anyone other than Xenova for providing the protections afforded to clients of Nomura or for providing advice in relation to the Offer or the New Xenova Shares. This announcement does not constitute an offer or an invitation to purchase any securities. This announcement does not constitute an offer of securities for sale in the United States and the New Xenova Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended, nor under any laws of any state of the United States, and the relevant clearances have not been and will not be obtained from the relevant authorities in Canada, Australia or Japan. Accordingly, unless an exemption under any applicable laws is available, the New Xenova Shares may not be offered, sold, resold, delivered or transferred directly or indirectly, in or into the United States, Canada, Australia or Japan or any other country outside the United Kingdom where such distribution may otherwise lead to a breach of law or other regulatory requirement, or to or for the benefit of US Persons. The Offer referred to in this announcement is not being made, directly or indirectly, in or into, or by use of the mails of or by any means of instrumentality (including, without limitation, facsimile transmissions, telex, telephone or internet) or interstate or foreign commerce of, or any facilities of a securities exchange of, the United States, nor is it being made, directly or indirectly, to or for the benefit of US Persons, nor is it being made, directly or indirectly, in or into Canada, Australia, or Japan unless an exemption under any applicable laws is available. This announcement is not being, and it must not be, mailed or otherwise forwarded, distributed or sent in, or into the United States, Canada, Australia or Japan and doing so may render invalid any purported acceptance of the Offer. This information is provided by RNS The company news service from the London Stock Exchange END OUPUUGQWUUPWGAW
1 Year KSB Chart |
1 Month KSB Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions